Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-06-14
2005-06-14
Seaman, D. Margaret (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
06906203
ABSTRACT:
The present invention is directed to substituted 4H-chromene and analogs thereof, represented by the general Formula I:wherein A, B, X, Y, Z and R5are defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention can be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
REFERENCES:
patent: 4698345 (1987-10-01), Dicker et al.
patent: 5281619 (1994-01-01), Dell et al.
patent: 5284868 (1994-02-01), Dell et al.
patent: 5434160 (1995-07-01), Dell et al.
patent: 5514706 (1996-05-01), Ambler et al.
patent: 5571818 (1996-11-01), Williams
patent: 5574034 (1996-11-01), Williams
patent: 5576325 (1996-11-01), Williams
patent: 5637589 (1997-06-01), Lee et al.
patent: 5726204 (1998-03-01), Lee et al.
patent: 5847165 (1998-12-01), Lee et al.
patent: 6160010 (2000-12-01), Uckun et al.
patent: 6221900 (2001-04-01), Uckun et al.
patent: 6258824 (2001-07-01), Yang
patent: 6294575 (2001-09-01), Uckun et al.
patent: 6303652 (2001-10-01), Uckun et al.
patent: 6365626 (2002-04-01), Uckun et al.
patent: 6388092 (2002-05-01), Yang
patent: 2003/0065018 (2003-04-01), Cai et al.
patent: 2003/0114485 (2003-06-01), Cai et al.
patent: 0 537 949 (1993-04-01), None
patent: 0 599 514 (1994-06-01), None
patent: 0 618 206 (1994-10-01), None
patent: 0 619 314 (1994-10-01), None
patent: WO 96/20721 (1996-07-01), None
patent: WO 98/24427 (1998-06-01), None
patent: WO 99/18856 (1999-04-01), None
patent: WO 99/54286 (1999-10-01), None
patent: WO 00/04901 (2000-02-01), None
patent: WO 02/092083 (2002-11-01), None
patent: WO 02/092594 (2002-11-01), None
patent: WO 03/096982 (2003-11-01), None
patent: WO 03/097806 (2003-11-01), None
Steedman's Medical Dictionary, 27th Edition, Pugh, M.B., et al., eds., Lippincott Williams & Wilkins, Philadelphia, PA, p. 897, col. 1, line 28, through p. 898, col. 1, line 8 (Jan. 2000).
“Anti-inflammatory Agents” in the “Product Category Index” of thePhysician's Desk Reference, 56th Edition, Medical Economics Company, Inc., Montvale, NJ, p. 206 (Nov. 2001).
Steedman's Medical Dictionary, 27th Edition, Pugh, M.B., et al., eds., Lippincott Williams & Wilkins, Philadelphia, PA, p. 276, col. 2, lines 57-63 (Jan. 2000).
“Antineoplastics,”In the“Product Category Index” of thePhysician's Desk Reference, 56th Edition, Medical Economics Company, Inc., Montvale, NJ, p. 206 (Nov. 2001).
Bode, A., and Dong, Z., “Apoptosis induction by arsenic: mechanisms of action and possible clinical applications for treating therapy-resistant cancers,”Drug Resist. Update 1:21-29, (Feb. 2000) PubMed, http://www
cbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11 4.9.8 accessed on Nov. 5, 2002.
Ding, Z., et al., “Resistance to apoptosis is correlated with the reduced caspase-3 activation and enhanced expression of antiapoptotic proteins in human cervical multidrug-resistant cells,” (Apr. 2000) PubMed, http://www
cbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10 7.5.3 accessed on Nov. 5, 2002.
Norgaard, J.M., and Hokland, P., “Biology of multiple drug resistance in acute leukemia,”Int J. Hematol. 72:290-297, (Oct. 2000) (see p. 290, seventh sentence), erratum 73:132 (Jan. 2001) PubMed, http://www
cbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11 1.8.5 accessed on Nov. 5, 2002.
Barinaga, M., “Cell Suicide: By ICE, Not Fire,”Science 263:754-756, American Association for the Advancement of Science (Feb. 1994).
Bloxham, J. et al., “Preparation of Some New Benzylidenemalononitriles by an SNAr Reaction: Application to Naphtho [1,2-b] pyran Synthesis,”Heterocycles 38:399-408, Elsevier Science Publishers B.V. (Feb. 1994).
Chandrasekhar, S. et al., “Identification of a Novel Chemical Series That Blocks Interleukin-1-Stimulated Metalloprotease Activity in Chondrocytes,”J. Pharmacol. Exp. Ther. 273: 1519-1528, Williams & Wilkins (1995).
McCarty, M.F., “Polyphenol-mediated inhibition of AP-1 transactivating activity may slow cancer growth by impeding angiogenesis and tumor invasiveness,”Medical Hypotheses 50:511-514, Harcourt Brace & Co. Ltd. (May 1998).
Paull, K.D. et al., “Identification of Novel Antimitotic Agents Acting at the Tubulin Level by Computer-assisted Evaluation of Differential Cytotoxicity Data,”Cancer Res. 52:3892-3900, American Association for Cancer Research (Jul. 1992).
Ruddon, R.W., “Biochemistry of Cancer,” inHolland Frei Cancer Medicine, Fifth Edition, section 1, chapter 7, B.C. Decker, accessed Apr. 12, 2002 at <http://www.ncbi.nlm.nih.gov/books/bv.fcgi?call=bv.View . . ShowSection&rid=cmed. chapter.d>.
Salvesen, G.S. and Dixit, V.M., “Caspase activation: The induced-proximity model,”Proc. Natl. Acad. Sci. USA 96:10964-10967, National Academy of Sciences of the United States of America (Sep. 1999).
Wolf, B.B., and Green, D.R., “Suidical Tendencies: Apoptotic Cell Death by Caspase Family Proteinases,”J. Biol. Chem. 274:20049-20052, The American Society for Biochemistry and Molecular Biology, Inc. (Jul. 1999).
Ellis, R.E. et al., “Mechanisms and Functions of Cell Death,”Annu. Rev. Cell. Biol. 7:663-698, Annual Reviews, Inc. (1991).
Friesen, C. et al., “Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells,”Nature Med.2:574-577, Nature Publishing Group (1996).
Los, M. et al., “Cross-Resistance of CD95- and Drug-Induced Apoptosis as a Consequence of Deficient Activation of Caspases (ICE/Ced-3 Proteases),”Blood 90:3118-3129, The American Society of Hematology (1997).
Orrenius, S., “Apoptosis: molecular mechanisms and implications for human disease,” J. Internal Med. 237:529-536, Blackwell Science Ltd. (1995).
Schmitt, E. et al., “The Bcl-xL and Bax-α control points: modulation of apoptosis induced by cancer chemotherapy and relation to TPCK-sensitive protease and caspase activation,”Biochem. Cell Biol. 75:301-314, NRC Canada (1997).
Sharanin, Y.A. et al., “Synthesis of 2-amino-4H-chromenes,”Chem. Abstracts 99:631, Abstract No. 212393z, American Chemical Society (1983).
Thornberry, N.A., “The caspase family of cysteine proteases,”Br. Med. Bull. 53:478-490, The Royal Society of Medicine Press Limited (1997).
Thornberry, N.A., “Caspases: key mediators of apoptosis,”Chemistry&Biology 5:R97-R103, Current Biology Ltd. (1998).
Wiernicki, T.R. et al., “Inhibition of Vascular Smooth Muscle Cell Proliferation and Arterial Intimal Thickening by a Novel Antiproliferative Naphthopyran,”J. Pharmacol. Exp. Ther. 278:1452-1459, Williams & Wilkins (1996).
Wyllie, A.H., “Cell death: a new classification separating apoptosis from necrosis,” inCell death in biology and pathology, Bowen, I.D. and R.A. Lockshin, eds., Chapman and Hall, 1981, pp. 9-34.
Wyllie, A.H. et al., “Cell Death: The Significance of Apoptosis,”Intl. Rev. Cytol. 68:251-306, Academic Press, Inc. (1980).
International Search Report for International Application No. PCT/US00/30374, mailed Jun. 15, 2001.
“aryl,”Hawley's Condensed Chemical Dictionary, Thirtheenth Edition, p. 94, John Wiley & Sons, Inc. (1997).
Al-Mousawi, S.M. et al., “Synthesis of New Condensed 2-Amino-4H-pyran-3-carbonitriles and of 2-Aminoquinoline-3-carbonitriles,”Organic Preparations and Procedures Int. 31:305-313, Organic Preparations and Procedures Inc. (Jun. 1999).
Batteux, F. et al., “Gene Therapy of Experimental Autoimmuine Thyroiditis by In Vivo Administration of Plasmid DNA Coding for Fas Ligand,”J. Immunol. 162:603-608, The American Association of Im
Cai Sui Xiong
Drewe John A.
Wang Yan
Cytovia, Inc.
Robinson Binta
Seaman D. Margaret
Sterne Kessler Goldstein & Fox P.L.L.C.
LandOfFree
Substituted 4H-chromene and analogs as activators of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted 4H-chromene and analogs as activators of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted 4H-chromene and analogs as activators of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3464063